PMID- 24167820
OWN - NLM
STAT- MEDLINE
DCOM- 20131202
LR  - 20220410
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
VI  - 123
IP  - 9
DP  - 2013 Sep
TI  - Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma 
      treated with radiotherapy.
PG  - 2154-60
AB  - OBJECTIVES/HYPOTHESIS: To examine the prognostic value of hypoxia inducible 
      factor HIF-1a, CA-IX, and OPN on clinical outcome in patients with T1-T2 
      supraglottic laryngeal squamous cell carcinoma (LSCC) treated with primarily 
      radiotherapy (RT). STUDY DESIGN: Retrospective cohort study. METHODS: Tumor 
      tissue sections of 60 patients with T1-T2 supraglottic LSCC treated with 
      primarily radiotherapy were assessed immunohistochemically for expression of 
      HIF-1a, CA-IX, and OPN. The relationship of protein expression and classical 
      clinical parameters with clinical outcome was studied, using Cox regression and 
      Kaplan-Meier survival analyses. RESULTS: Neither HIF-1a nor CA-IX was of 
      prognostic significance toward local control or overall survival in T1-T2 
      supraglottic LSCC. Cox regression survival analysis showed no relation between 
      HIF-1a or CA-IX expression and local control (HR [hazard ratio] 1.07, CI [95% 
      confidence interval] 0.29-3.87; HR 0.34, CI 0.04-2.58). Furthermore, OPN 
      expression was not associated with local control (HR 1.37, CI 0.45-4.17) and 
      overall survival (HR 0.99, CI 0.44-2.21). Our earlier findings in T1-T2 glottic 
      LSCC (Schrijvers et al., 2008) could not be confirmed. CONCLUSION: The absence of 
      prognostic significance for HIF-1a and CA-IX toward local control in supraglottic 
      LSCC, unlike glottic LSCC, suggests that supraglottic LSCC might represent 
      another biological entity.
FAU - Wachters, Jan E
AU  - Wachters JE
FAU - Schrijvers, Michiel L
AU  - Schrijvers ML
FAU - Slagter-Menkema, Lorian
AU  - Slagter-Menkema L
FAU - Mastik, Mirjam
AU  - Mastik M
FAU - de Bock, Geertruida H
AU  - de Bock GH
FAU - Langendijk, Johannes A
AU  - Langendijk JA
FAU - Kluin, Philip M
AU  - Kluin PM
FAU - Schuuring, Ed
AU  - Schuuring E
FAU - van der Laan, Bernard F A M
AU  - van der Laan BF
FAU - van der Wal, Jacqueline E
AU  - van der Wal JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Peptide Fragments)
RN  - 0 (osteopontin (1-168), human)
RN  - 106441-73-0 (Osteopontin)
RN  - EC 4.2.1.1 (CA9 protein, human)
RN  - EC 4.2.1.1 (Carbonic Anhydrase IX)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/*metabolism
MH  - Biomarkers, Tumor/*analysis
MH  - Carbonic Anhydrase IX
MH  - Carbonic Anhydrases/*metabolism
MH  - Carcinoma, Squamous Cell/*mortality/pathology/radiotherapy
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*analysis
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*mortality/pathology/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Staging
MH  - Osteopontin/*metabolism
MH  - Peptide Fragments/*metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2013/10/30 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/10/30 06:00
PHST- 2013/10/30 06:00 [entrez]
PHST- 2013/10/30 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1002/lary.23831 [doi]
PST - ppublish
SO  - Laryngoscope. 2013 Sep;123(9):2154-60. doi: 10.1002/lary.23831.